ArticleMolecular neurobiology2025
Nuclear MicroRNA-124-3p Promotes Neurite Outgrowth After Spinal Cord Injury by Enhancing Cttn Transcription.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dual evidence reveals the therapeutic efficacy of exosome-delivered miR-124-3p in spinal cord injury via a novel CTDSP1/WNT/β-catenin mechanism.Spinal cord · 2026Article
- RNA-binding protein PTBP1 mediates HSV-1 attachment and infection through regulation of heparan sulfate 3-O-sulfotransferase gene expression.Cell & bioscience · 2025Article
- Cerebrospinal fluid extracellular vesicle-derived miR-9-3p in spinal cord injury with neuroprotective implications and biomarker development.Communications biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outgrowth of motor neurons needs to be enhanced for the efficient recovery of sensory and movement abilities after nerve injury. The microRNA miR-124-3p can repair spinal cord injury (SCI) and promote neurite outgrowth. In this study, we aimed to investigate the effect of miR-124-3p on neurite outgrowth and the mechanism underlying its effect on SCI. Rats with SCI were intrathecally injected with agomiR-124 (miR-124-3p agomiR) for 14 days. The agomiR-124 improved locomotor functions were observed with open-field scoring systems. The levels of miR-124-3p and Cortactin across three weeks, and neuronal biomarkers NF200, Tuj1, Map2 and NeuN post 6 weeks were reduced in rats with SCI, which were reverted with agomiR-124 treatment. The wound scratch assay showed that agomiR-124 enhanced outgrowth of neurites in PC12 cell-derived neuronal like cells. Silencing of Cttn reduced the numbers of neurites and growth cones, while pcDNA-Cttn exerted an opposite effect. The enhanced outgrowth of neurites by agomiR-124 can be reverted by co-treated si-Cttn. Finally, the interactions among miR-124-3p, IPO8, Ago1/2, and the Cttn promoter were verified in PC12 cells through RNA immunoprecipitation, RNA pull-down, and chromatin immunoprecipitation assays. Our results showed that miR-124-3p enhanced the function of neurons and promoted neurite outgrowth following SCI, at least partly by targeting the promoter of Cttn and activating its transcription. These findings elucidated the mechanism underlying the neuroprotective effects of miR-124-3p and revealed the therapeutic ability of the two molecules as targets associated with SCI.
Indexed as
Identifiers
40044957What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.